Toxicology News and Research

Latest Toxicology News and Research

Prenatal exposure to PCBs impacts reproductive function in offspring

Prenatal exposure to the environmental contaminants polychlorinated biphenyls, or PCBs, causes long-term changes to the developing brain that have adverse effects on reproductive function later in life, a new study finds. Results will be presented Saturday at The Endocrine Society's 94th Annual Meeting in Houston.

28 Jun 2012

Seahorse Bioscience launches XF Palmitate-BSA FAO Reagent for FAO assays

Seahorse Bioscience, the world leader in manufacturing instrumentation and assay kits for measuring cellular metabolism, has announced the launch of its newest product, the XF Palmitate-BSA FAO Reagent, eliminating the need for radioactivity in fatty acid oxidation (FAO) assays.

27 Jun 2012

BV treatment: full enrolment for phase 2 and first phase 3 trial

Starpharma Holdings Ltd (ASX:SPL; OTCQX: SPHRY) is pleased to report that recruitment is now 100% complete for its Phase 2 clinical trial to investigate the ability of VivaGel® to prevent the recurrence of BV, and also for the first of two pivotal Phase 3 studies of VivaGel® for the treatment of BV.

25 Jun 2012

FDA issues CRL to Repligen's RG1068 NDA for treatment of pancreatitis

Repligen Corporation today announced that it has received a Complete Response Letter (CRL) from the U.S. Food & Drug Administration (FDA) regarding the Company's New Drug Application (NDA) for RG1068.

23 Jun 2012

Long QT Syndrome may cause unexplained ExD deaths

The headlines are often filled with this scenario: a person displaying violent, bizarre and agitated behavior is subdued by law enforcement personnel and later dies in custody. It appears to be a case of police brutality - but is it? According to William P. Bozeman, M.D., an emergency medicine physician at Wake Forest Baptist Medical Center, some of these deaths may be caused by an abnormal cardiac condition called Long QT Syndrome, compounded by a situation of Excited Delirium (ExD) Syndrome.

21 Jun 2012

Study identifies critical neurological factor in aggression

Pathological rage can be blocked in mice, researchers have found, suggesting potential new treatments for severe aggression, a widespread trait characterized by sudden violence, explosive outbursts and hostile overreactions to stress.

20 Jun 2012

Thermo Fisher Scientific introduces research-grade FT-IR system

Thermo Fisher Scientific Inc., the world leader in serving science, extended its leading FT-IR spectrometry platform by introducing the first research-grade FT-IR system designed for simple one-touch operation.

From Thermo Fisher Scientific Inc. 18 Jun 2012

ABL to perform process development and cGMP manufacturing of recombinant scuPA

Advanced BioScience Laboratories, Inc. (ABL) will perform process development and cGMP manufacturing of recombinant scuPA, an enzyme therapy candidate for patients with pleural loculation or scarring surrounding the lung.

14 Jun 2012

New set of computer models predicts negative side effects in current drugs

A new set of computer models has successfully predicted negative side effects in hundreds of current drugs, based on the similarity between their chemical structures and those molecules known to cause side effects, according to a paper appearing online this week in the journal Nature.

12 Jun 2012

Fate Therapeutics, BD Biosciences introduce first collaborative iPSC-related product

Fate Therapeutics, Inc. in collaboration with BD Biosciences, a segment of BD (Becton, Dickinson and Company), today announced the introduction of the first induced pluripotent stem cell (iPSC)-related product resulting from the collaboration between the two companies.

From BD (Becton, Dickinson and Company) 11 Jun 2012

Cebix announces data from Ersatta Phase 1 study on type 1 diabetes

Cebix Incorporated today announced that data from a Phase 1 study demonstrated that Ersatta, the company's long-acting form of C-peptide, was well tolerated with no serious adverse events in patients with type 1 diabetes and exhibited a pharmacokinetic profile consistent with once-weekly dosing.

11 Jun 2012

Strand, Trovagene enter MOU to license and validate HPV assay technology

Trovagene, Inc., a developer of trans-renal molecular diagnostics, and Strand Life Sciences Pvt Ltd., of Bangalore, India, have entered into a Memorandum of Understanding (MOU) to license and validate Trovagene's proprietary Human Papillomavirus (HPV) urine test and High Risk HPV DNA Assay for clinical diagnostic and carrier screening use in India and countries in the South Asian Association for Regional Cooperation.

8 Jun 2012

Arrowhead initiates final IND-enabling steps for ARC-520 to treat HBV

Arrowhead Research Corporation, a targeted therapeutics company, today announced that its hepatitis B virus (HBV) program has completed all internal preclinical requirements and has named a clinical candidate.

7 Jun 2012

Increased risk of bladder cancer linked to diabetes drug

Pioglitazone - a drug used to treat type 2 diabetes - is associated with an increased risk of bladder cancer, finds a study published on bmj.com today.

1 Jun 2012

Researchers identify novel biomarkers that could confirm exposure to radiation

Researchers at the Medical College of Wisconsin have identified novel biomarkers that could be used to confirm exposure to damaging radiation in large groups of people potentially exposed to unknown and variable doses for the purpose of triage and treatment.

23 May 2012

Receptos to present scientific podium presentation about RPC1063 at DDW 2012

Receptos Inc. today announced that company personnel will deliver a scientific podium presentation about RPC1063 at the Digestive Disease Week (DDW) annual meeting at 9 a.m. PDT on Sunday, May 20, 2012 at the San Diego Convention Center in San Diego, California. DDW attracts thousands of physicians, researchers, and academics from around the world to share the latest research in gastrointestinal health topics, for which DDW is the premier scientific conference.

19 May 2012

JAT accepts five scientific articles co-authored by UCSD doctoral pharmacy students

The Millennium Research Institute (MRI), a nonprofit national research center formed in 2010, and the Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of California, San Diego (UCSD) announced today five scientific articles co-authored by UCSD doctoral pharmacy students have been accepted by the Journal of Analytical Toxicology.

19 May 2012